[{"Assets_0_Q3_USD":1173623000.0,"CommonStockSharesOutstanding_0_Q3_shares":50186299.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":207564000.0,"NetIncomeLoss_1_Q3_USD":20945000.0,"NetIncomeLoss_3_Q3_USD":66181000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":51486996.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":51189680.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":50071632.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":49851082.0,"EarningsPerShareBasic_1_Q3_USD":0.42,"EarningsPerShareBasic_3_Q3_USD":1.33,"EarningsPerShareDiluted_1_Q3_USD":0.41,"EarningsPerShareDiluted_3_Q3_USD":1.29,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":173653000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":511667000.0,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20181102"}]